BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oru E, Trickey A, Shirali R, Kanters S, Easterbrook P. Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis. Lancet Glob Health 2021;9:e431-45. [PMID: 33639097 DOI: 10.1016/S2214-109X(20)30505-2] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 49.0] [Reference Citation Analysis]
Number Citing Articles
1 Suan MAM, Chan HK, Sem X, Shilton S, Hassan MRA. Diagnostic performance of two non-invasive biomarkers used individually and in sequential combination for cirrhosis associated with hepatitis C virus infection. Sci Rep 2022;12:20153. [PMID: 36418369 DOI: 10.1038/s41598-022-24612-9] [Reference Citation Analysis]
2 Malaguti A, Byrne CJ, Sani F, Power K, Eriksen A, Dillon JF. Drug network identification predicts injecting risk behavior among people who inject drugs on hepatitis C virus treatment in Tayside, Scotland. Behavioral Medicine 2022. [DOI: 10.1080/08964289.2022.2142501] [Reference Citation Analysis]
3 Villar LM, de Lima MP, Cruz HM, de Paula VS, Scalioni LP, Flores GL, Carvalho-Costa FA, Parente CC, Coelho MRCD, de Albuquerque ACC, Milagres FAP, Cruz MS, Andrade TM, Motta-Castro ARC, da Mota JC, Lewis-Ximenez LL, Bastos FI. Feasibility of dried blood spot for hepatitis C diagnosis in vulnerable subjects and people living in remote areas from Brazil. BMC Infect Dis 2022;22:804. [PMID: 36303137 DOI: 10.1186/s12879-022-07717-4] [Reference Citation Analysis]
4 Ivanova Reipold E, Fajardo E, Juma E, Bukusi D, Bermudez Aza E, Jamil MS, Johnson CC, Farquhar C, Easterbrook P, Monroe-wise A. Usability and acceptability of oral fluid hepatitis C self-testing among people who inject drugs in Coastal Kenya: a cross-sectional pilot study. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07712-9] [Reference Citation Analysis]
5 I-COPTIC Collaboration . I-COPTIC: Implementation of community pharmacy-based testing for hepatitis C: Delphi consensus protocol. Int J Pharm Pract 2022:riac064. [PMID: 35997159 DOI: 10.1093/ijpp/riac064] [Reference Citation Analysis]
6 Marshall AD, Martinello M, Treloar C, Matthews GV. Perceptions of hepatitis C treatment and reinfection risk among HIV-positive men who have sex with men and engage in high risk behaviours for hepatitis C transmission: The CEASE qualitative study. Int J Drug Policy 2022;109:103828. [PMID: 35994937 DOI: 10.1016/j.drugpo.2022.103828] [Reference Citation Analysis]
7 Pérez-hernández FJ, Morales-arráez DE, Amaral-gonzález C, González-méndez Y, Ortega-sánchez JA, de la Barreda Heuser R, Abreu Alonso I, Ramos López L, Alarcón-fernández O, Carrillo-palau M, Hernández-guerra M. Asynchronous electronic consultation between primary care and specialized care proved effective for continuum of care for viraemic hepatitis C patients. Gastroenterología y Hepatología 2022. [DOI: 10.1016/j.gastrohep.2022.08.003] [Reference Citation Analysis]
8 Conway A, Valerio H, Alavi M, Silk D, Treloar C, Hajarizadeh B, Marshall AD, Martinello M, Milat A, Dunlop A, Murray C, Prain B, Henderson C, Amin J, Read P, Marks P, Degenhardt L, Hayllar J, Reid D, Gorton C, Lam T, Christmass M, Wade A, Montebello M, Dore GJ, Grebely J; ETHOS Engage Study Group. A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study. Viruses 2022;14:1555. [PMID: 35891535 DOI: 10.3390/v14071555] [Reference Citation Analysis]
9 Valerio H, Alavi M, Conway A, Silk D, Treloar C, Martinello M, Milat A, Dunlop A, Murray C, Henderson C, Amin J, Read P, Marks P, Degenhardt L, Stevens A, Prain B, Hayllar J, Reid D, Montebello M, Wade A, Christmass M, Cock V, Dore GJ, Grebely J. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study. International Journal of Drug Policy 2022;105:103706. [DOI: 10.1016/j.drugpo.2022.103706] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Byrne CJ, Radley A, Inglis SK, Beer L, Palmer N, Duc Pham M, Allardice K, Wang H, Robinson E, Hermansson M, Semizarov D, Healy B, Doyle JS, Dillon JF. Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: an international randomised controlled trial. Aliment Pharmacol Ther 2022;55:1512-23. [PMID: 35538396 DOI: 10.1111/apt.16953] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Gupta N, Manirambona L, Shumbusho F, Kabihizi J, Murangwa A, Serumondo J, Makuza JD, Nsanzimana S, Muvunyi CM, Mukabatsinda C, Musabeyezu E, Camus G, Grant PM, Kateera F. Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial. The Lancet Gastroenterology & Hepatology 2022;7:542-51. [DOI: 10.1016/s2468-1253(21)00399-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
12 Kateera F, Shumbusho F, Manirambona L, Kabihizi J, Murangwa A, Serumondo J, Makuza JD, Nsanzimana S, Muvunyi CM, Kabakambira JD, Sylvain H, Camus G, Grant PM, Gupta N. Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial. The Lancet Gastroenterology & Hepatology 2022;7:533-41. [DOI: 10.1016/s2468-1253(21)00398-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Nevola R, Rosato V, Conturso V, Perillo P, Le Pera T, Del Vecchio F, Mastrocinque D, Pappalardo A, Imbriani S, Delle Femine A, Piacevole A, Claar E. Can Telemedicine Optimize the HCV Care Cascade in People Who Use Drugs? Features of an Innovative Decentralization Model and Comparison with Other Micro-Elimination Strategies. Biology 2022;11:805. [DOI: 10.3390/biology11060805] [Reference Citation Analysis]
14 Tang W, Tao Y, Fajardo E, Reipold EI, Chou R, Tucker JD, Easterbrook P. Diagnostic Accuracy of Point-of-Care HCV Viral Load Assays for HCV Diagnosis: A Systematic Review and Meta-Analysis. Diagnostics 2022;12:1255. [DOI: 10.3390/diagnostics12051255] [Reference Citation Analysis]
15 Ghosh A, Mahintamani T, Premkumar M, Basu D, Singh V, Duseja A, Subodh Bn, Mohindra R, Sharma A, Arora SK. Multidisciplinary and Integrated Treatment for Substance Use Disorders and Hepatitis C in an Addiction Treatment Service in India. Indian Journal of Psychological Medicine. [DOI: 10.1177/02537176221086013] [Reference Citation Analysis]
16 Kaur H, Dhiman RK, Kulkarni AV, Premkumar M, Singh V, Duseja AK, Grover S, Grover GS, Roy A, Verma N, De A, Taneja S, Mehtani R, Mishra S, Kaur H. Improvement of chronic HCV infection-related depression, anxiety, and neurocognitive performance in persons achieving SVR-12: A real-world cohort study. J Viral Hepat 2022;29:395-406. [PMID: 35266624 DOI: 10.1111/jvh.13668] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Vu BN, Tuan KD, Tran AK, Tran LK, Green K, Nguyen KT, Cao PD. Community‐based and HIV integrated testing for hepatitis B and C among key populations in Vietnam. Clinical Liver Disease 2022;19:131-7. [DOI: 10.1002/cld.1221] [Reference Citation Analysis]
18 Wang AE, Hsieh E, Turner BJ, Terrault N. Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts. J Gen Intern Med 2022. [PMID: 35484367 DOI: 10.1007/s11606-022-07628-9] [Reference Citation Analysis]
19 Cunningham EB, Wheeler A, Hajarizadeh B, French CE, Roche R, Marshall AD, Fontaine G, Conway A, Valencia BM, Bajis S, Presseau J, Ward JW, Degenhardt L, Dore GJ, Hickman M, Vickerman P, Grebely J. Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2022:S2468-1253(21)00471-4. [PMID: 35303490 DOI: 10.1016/S2468-1253(21)00471-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
20 Adee M, Zhong H, Reipold EI, Zhuo Y, Shilton S, Chhatwal J. Cost-Effectiveness of a Core Antigen–Based Rapid Diagnostic Test for Hepatitis C. Value in Health 2022. [DOI: 10.1016/j.jval.2022.01.004] [Reference Citation Analysis]
21 Winter RJ, Holmes JA, Papaluca TJ, Thompson AJ. The Importance of Prisons in Achieving Hepatitis C Elimination: Insights from the Australian Experience. Viruses 2022;14:497. [DOI: 10.3390/v14030497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Rupasinghe D, Choi JY, Kumarasamy N, Pujari S, Sun LP, Merati TP, Lee MP, Kinh NV, Kiertiburanakul S, Do CD, Avihingsanon A, Ross J, Jiamsakul A; o n behalf of IeDEA Asia-Pacific. Viral hepatitis and the cascade of care among people living with HIV in the Asia-Pacific. HIV Med 2022. [PMID: 35218151 DOI: 10.1111/hiv.13280] [Reference Citation Analysis]
23 Marshall AD, Rance J, Grebely J, Treloar C. 'Not just one box that you tick off' - Deconstructing the hepatitis C care cascade in the interferon-free direct acting antiviral era from the client perspective. Int J Drug Policy 2022;102:103610. [PMID: 35151085 DOI: 10.1016/j.drugpo.2022.103610] [Reference Citation Analysis]
24 Dusheiko G, Carey I. Global elimination of hepatitis C: a warning from the data. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00009-7] [Reference Citation Analysis]
25 Draper B, Yee WL, Pedrana A, Kyi KP, Qureshi H, Htay H, Naing W, Thompson AJ, Hellard M, Howell J. Reducing liver disease-related deaths in the Asia-Pacific: the important role of decentralised and non-specialist led hepatitis C treatment for cirrhotic patients. Lancet Reg Health West Pac 2022;20:100359. [PMID: 35024676 DOI: 10.1016/j.lanwpc.2021.100359] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Von den Hoff DW, Berden FAC, Drenth JPH, Schellekens AFA, HepNed, NISPA. Implementation of a decentralized hepatitis C care pathway for people who use drugs in Dutch addiction care. Study protocol for the Hepatitis C: chain of addiction care (CAC) project. Addict Sci Clin Pract 2022;17:67. [DOI: 10.1186/s13722-022-00350-1] [Reference Citation Analysis]
27 Klein MB. Simplifying HCV treatment: a pathway to elimination and model for delivering health care to vulnerable populations. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00467-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399:61-116. [PMID: 34863359 DOI: 10.1016/S0140-6736(21)01701-3] [Cited by in Crossref: 53] [Cited by in F6Publishing: 66] [Article Influence: 53.0] [Reference Citation Analysis]
29 Markby J, Shilton S, Sem X, Chan HK, Md Said R, Siva S, Zainuddin Z, Abu Bakar N, Omar H, Ruiz RJI, Gaeddert M, Tyshkovskiy A, Adee M, Chhatwal J, Kumar S, Piedagnel JM, Mohd Zain R, Menétrey C, Yuswan F, Hairizan Nasir N, Andrieux-Meyer I, Ismail F, Zakaria R, Hasim R, Murad S, Easterbrook P, Hassan MRA. Assessing the impact of simplified HCV care on linkage to care amongst high-risk patients at primary healthcare clinics in Malaysia: a prospective observational study. BMJ Open 2021;11:e055142. [PMID: 34952885 DOI: 10.1136/bmjopen-2021-055142] [Reference Citation Analysis]
30 Conway B, Rodriguez-tajes S, Garcia-retortillo M, Pérez-hernandez P, Teti E, Ryan P, Fraser C, Macedo G, Morano Amado LE, Lédinghen VD, Fenech M, Martins A, Guerra-veloz MF, Ntalla I, Ramroth H, Vanstraelen K, Hernandez C, Mertens M, O’loan J. Real-world evidence of sofosbuvir/velpatasvir as an effective and simple hepatitis C virus treatment and elimination tool in homeless populations. Future Virology. [DOI: 10.2217/fvl-2021-0266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Chan PL, Le LV, Ishikawa N, Easterbrook P. Regional progress towards hepatitis C elimination in the Western Pacific Region, 2015-2020. Glob Health Med 2021;3:253-61. [PMID: 34782866 DOI: 10.35772/ghm.2021.01065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
32 Dhiman RK, Grover GS, Premkumar M, Roy A, Taneja S, Duseja A, Arora S; MMPHCRF Investigators. Outcomes of Real-World Integrated HCV Microelimination for People Who Inject Drugs: An expansion of the Punjab Model. EClinicalMedicine 2021;41:101148. [PMID: 34712928 DOI: 10.1016/j.eclinm.2021.101148] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Von den Hoff DW, Berden FAC, Schellekens AFA. If the mountain won't come to Mohammed, then Mohammed must go to the mountain: Decentralisation of hepatitis C care for people who use drugs. United European Gastroenterol J 2021;9:1101-2. [PMID: 34687156 DOI: 10.1002/ueg2.12167] [Reference Citation Analysis]
34 Lazarus JV, Herranz A, Picchio CA, Villota-Rivas M, Rodríguez A, Alonso JM, Moratinos A, Perrotta A, Tegeo E, Bibiloni F, Buti M, Vilella À. Eliminating hepatitis C on the Balearic Islands, Spain: a protocol for an intervention study to test and link people who use drugs to treatment and care. BMJ Open 2021;11:e053394. [PMID: 34675021 DOI: 10.1136/bmjopen-2021-053394] [Reference Citation Analysis]
35 Serumondo J, Shilton S, Nshimiyimana L, Karame P, Dushimiyimana D, Fajardo E, Remera E, Rwibasira GN, Martínez-Pérez GZ. Values and preferences for hepatitis C self-testing among the general population and healthcare workers in Rwanda. BMC Infect Dis 2021;21:1064. [PMID: 34649503 DOI: 10.1186/s12879-021-06773-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
36 Sun J, Cheng H, Hassan MRA, Chan HK, Piedagnel JM. What China can learn from Malaysia to achieve the goal of "eliminate hepatitis C as a public health threat" by 2030 - a narrative review. Lancet Reg Health West Pac 2021;16:100261. [PMID: 34590064 DOI: 10.1016/j.lanwpc.2021.100261] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
37 Cordie A, Mohamed R, Sonderup MW, Wendy Spearman C, Medhat MA, Debzi N, Desalegn H, Esmat G. Hepatitis C elimination in Africa: Seizing the moment for hepatitis-C free future. Arab J Gastroenterol 2021;22:249-51. [PMID: 34531133 DOI: 10.1016/j.ajg.2021.07.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Martínez-Pérez GZ, Nikitin DS, Bessonova A, Fajardo E, Bessonov S, Shilton S. Values and preferences for hepatitis C self-testing among people who inject drugs in Kyrgyzstan. BMC Infect Dis 2021;21:609. [PMID: 34171990 DOI: 10.1186/s12879-021-06332-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
39 Reipold EI, Farahat A, Elbeeh A, Soliman R, Aza EB, Jamil MS, Johnson CC, Shiha G, Easterbrook P. Usability and acceptability of self-testing for hepatitis C virus infection among the general population in the Nile Delta region of Egypt. BMC Public Health 2021;21:1188. [PMID: 34158006 DOI: 10.1186/s12889-021-11169-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]